市场调查报告书
商品编码
1403421
至 2030 年女性用医疗设备市场预测:按产品类型、应用、最终用户和地区分類的全球分析Women's Health Devices Market Forecasts to 2030 - Global Analysis By Product (Labor & Delivery, Critical Care, Contraceptives, Surgical, Diagnostics and Other Products), Type, Application, End User and By Geography |
根据 Stratistics MRC 的数据,2023 年全球女性用医疗设备市场规模为 524 亿美元,预计预测期内复合年增长率为 11.3%,到 2030 年将达到 1,101 亿美元。
用于生育治疗、计划生育、孕产妇和月经健康的产品被归类为女性健康用品。这些小工具包括专门用于治疗女性特有的疾病和健康问题的各种医疗设备。这些设备解决了许多女性健康问题,包括更年期、怀孕、生产和生殖健康。它还治疗乳腺癌、子宫颈癌和骨盆底问题等疾病。
根据国际癌症研究机构的数据,乳癌已超过肺癌,成为女性最常被诊断的癌症类型。 2020年,报告了约230万新发乳癌病例。 2020年,大约将有920万人新诊断出癌症,440万人将死亡。
提高对妇女健康的认识与关注
由于人们对女性健康及其相关活动的认识不断增强,小工具的诞生是为了满足特定的医疗需求。由于公共卫生和教育方面的努力,对这些小工具的需求也在增加。女性可以使用这些小工具追踪健康指标的变化,这些小工具通常强调预防性健康措施并鼓励早期疗育和预防活动。这些方面正在推动市场扩张。
缺乏市场渗透
儘管对女性用医疗设备的需求重要且不断增长,但与已开发国家相比,新兴地区大众对许多女性疾病的认识较低。对于影响妇女健康的疾病的许多征兆,人们缺乏许多了解,而这些疾病可以透过适当的诊断和治疗工具轻鬆治疗和逆转。这些严重损害了这些国家妇女的生存率。因此,这个因素可能会阻碍市场的扩张。
盛行率上升
近几十年来,由于多种原因,包括诊断技术的技术进步以及导致引入预防性医疗保健的意识提高,妇女健康问题的总体发病率大幅增加。由于发病率显着增加,大量患者现在患有慢性和残疾疾病,这些疾病对他们的日常功能产生负面影响,并显着增加了他们的死亡风险。这些都是影响市场拓展的方面。
高可维护性和复杂性
这些设备需要昂贵的定期维护和修理。由于需要专业技术人员和零件,费用可能会增加。如果设备需要维修或维护,可能会出现一段时间的停机时间。因此,预订和医疗服务可能会受到影响。有些小工具复杂且精密,因此难以维护。这种复杂性可能会导致维修时间更长。因此,这个因素可能会阻碍市场的成长。
COVID-19 的爆发导致该行业主要参与者的收入下降。疫情期间,排卵监测仪、子宫内避孕器、月经痛管理和女性用保险套等女性用避孕器的需求下降。女性用避孕器具销售下降的原因是对消费者流动的限制和严格的社交距离规则阻碍了社交聚会。
预计在预测期内,慢性病领域将是最大的。
预计慢性病细分市场将成为预测期内最大的细分市场。饮食的改变、缺乏运动和生活方式的改变正在增加女性糖尿病、癌症和心臟病等慢性疾病的盛行率。影响女性最常见的慢性疾病是癌症。由于女性肺癌、卵巢、结肠癌和乳腺癌等癌症发生率的增加,这一领域正在急剧增长。
预计医院和诊所产业在预测期内将经历最高的复合年增长率。
预计医院和诊所产业在预测期内将经历最高的复合年增长率。这可能只是由于人们越来越倾向于使用医院来治疗大多数疾病。该行业成长的主要驱动力是公立和私立医院使用量的增加、私人诊所的成长、医院专门妇女病房的可用性、医院诊断和治疗基础设施的加强及其发展。
由于女性人口众多,预计北美在预测期内将占据最大的市场占有率。由于妇女医疗保健方面的高支出和对高科技设备的高需求,预计该地区将具有优势。该地区的主要市场参与者预计将继续增加在研发、临床研究和引进创新健康设备方面的支出,进一步增加市场需求。
预计亚太地区在预测期内将维持最高的复合年增长率。由于政府活性化力度促进该国性别平等,女性人口迅速增加。此外,女性劳动参与率的上升也增加了女性的可支配所得。女性族群中癌症、糖尿病、心血管疾病和呼吸系统疾病等各种慢性疾病的盛行率上升预计将促进市场成长。
According to Stratistics MRC, the Global Women's Health Devices Market is accounted for $52.4 billion in 2023 and is expected to reach $110.1 billion by 2030 growing at a CAGR of 11.3% during the forecast period. Products for fertility, family planning, and maternal and menstrual health are classified as women's health gadgets. These gadgets include a broad variety of medical equipment made especially to treat illnesses or health problems that are exclusive to women. These devices address a number of women's health issues, including menopause, pregnancy, delivery, and reproductive health. They also address illnesses including breast and cervical cancer, pelvic floor problems, and more.
According to the International Agency for Research on Cancer, the female breast cancer has become the most diagnosed type of cancer by surpassing the lungs cancer. Around 2.3 million new cases of breast cancer were reported in 2020. Around 9.2 million new cases of cancer and 4.4 million cancer deaths in female were reported in 2020.
The creation of gadgets that meet particular medical demands has been aided by increased awareness of women's health concerns and activities cantered around them. The need for these gadgets has also grown as a result of public health initiatives and educational initiatives. Women may follow changes in their health markers using these gadgets, which generally highlight preventative health measures and encourage early intervention and preventive activities. These are the aspects fostering the market's expansion.
Despite a crucial and increasing demand for women's health equipment, awareness of many women's diseases is poor among the general public in emerging regions, as opposed to industrialized countries. A great deal of knowledge is lacking on the many signs of disorders affecting women's health that are readily treated or resolved with the right diagnosis and treatment tools. These seriously impair women's survival rates in these nations. Therefore, this factor might impede market expansion.
The general incidence of women's health problems has risen considerably in recent decades as a result of numerous reasons, including technical advances in diagnostic technologies and improved awareness, which has led to the adoption of preventative care. Due to the notable increase in incidence, there is now a substantial patient population with chronic and crippling illnesses that have a negative impact on daily functioning and significantly increase the risk of death. These are the aspects affecting the market's expansion.
These gadgets require pricey routine upkeep and repairs. Higher expenses may result from the demand for specialized technicians or parts. There may be a period of inactivity when equipment needs to be serviced or maintained. This might affect arranged appointments or healthcare services. Some gadgets are difficult to maintain because they are complicated and sophisticated. Lengthier repair durations may also result from this complexity. As a result, this factor may prevent market growth.
The COVID-19 epidemic caused a reduction in income for major participants in the industry. During the pandemic, there was a decrease in the demand for female contraceptive goods, including ovulation monitors, intrauterine devices, menstrual pain management, and female condoms. Sales of female contraceptive devices fell as a result of consumer mobility constraints and stringent social distance rules that discouraged socializing.
The chronic diseases segment is expected to be the largest during the forecast period. The incidence of chronic illnesses, including diabetes, cancer, heart disease, and other conditions, is increasing among women due to dietary changes, physical inactivity, and altered lifestyles. The most common chronic illness affecting women is cancer. This sector has grown dramatically as a result of the increasing incidence of lung cancer, ovarian cancer, colon cancer, and breast cancer among women.
The hospitals & clinics segment is expected to have the highest CAGR during the forecast period. This may be attributed only to the population's growing inclination towards using hospitals for treatment of most illnesses. The main drivers of the segment's growth have been the increased use of both public and private hospitals, the growth of private clinics, the availability of specialized wards for women at hospitals, and the strength and development of the hospital's infrastructure for diagnosis and treatment.
North America is projected to hold the largest market share during the forecast period owing to the presence of huge female population in the region. High spending on women's health care and a correspondingly high demand for high-tech devices are expected to contribute to the region's dominance. It is anticipated that the leading market players in the area will continue to increase their spending in R&D, clinical studies, and the introduction of innovative health gadgets, which will further increase demand in the market.
Asia Pacific is projected to hold the highest CAGR over the forecast period. The increased government initiatives to promote gender equality in the nation have resulted in a surge in the women population. Moreover, the rising participation of women in the workforce is resulting in the increased disposable income of the women. The rising prevalence of various chronic diseases such as cancer, diabetes, cardiovascular diseases, and respiratory disorders among the women population is expected to augment the growth of the market.
Some of the key players in Women's Health Devices market include Koninklijke Philips, Siemens AG, Prestige Consumer Healthcare, Inc., Caldera Medical, MedGyn Products, Medline Industries, Abbott Laboratories, Carestream Health, GE Healthcare, F. Hoffmann-La Roche, Hologic, CooperSurgical, Inc. , Innovative Health Diagnostic and BioSkryb Genomics.
In December 2022, CooperSurgical, Inc. partnered with Ostro to launch a new consumer engagement solution for CooperSurgical's hormone-free IUD, Paragard. Paragard is an FDA-approved intrauterine device that prevents pregnancy up to 10 years.
In October 2022, BioSkryb Genomics signed a multi-year agreement with Cooper Genomics to license BioSkryb's proprietary genomic amplification technology. Cooper Genomics will utilize BioSkryb technology to enhance its preimplantation genetic testing (PGT) capabilities.